PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTaurolidine
Taurolidine
Defencath (taurolidine) is a small molecule pharmaceutical. Taurolidine was first approved as Defencath on 2023-11-15.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Defencath
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Heparin sodium
+
Taurolidine
Tradename
Company
Number
Date
Products
DEFENCATHCorMedixN-214520 RX2023-11-15
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
defencathNew Drug Application2024-12-23
Agency Specific
FDA
EMA
Expiration
Code
HEPARIN SODIUM / TAUROLIDINE, DEFENCATH, CORMEDIX
2033-11-15GAIN
2028-11-15NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Heparin Sodium / Taurolidine, Defencath, Cormedix
117381202042-04-15DS, DP
76961822025-05-16DS, DPU-3774
85413932024-11-02DS, DPU-3774
93390362024-11-02DS, DP
ATC Codes
B: Blood and blood forming organ drugs
B05: Blood substitutes and perfusion solutions
B05C: Irrigating solutions, blood substitutes and perfusion
B05CA: Antiinfective irrigating solutions
B05CA05: Taurolidine
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805EFO_0001420A41.92114
InfectionsD007239EFO_00005442114
Communicable diseasesD0031412114
Catheter-related infectionsD0554991113
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.611
Renal insufficiencyD051437N1911
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTaurolidine
INNtaurolidine
Description
Taurolidine is a thiadiazinane.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1
Identifiers
PDB
CAS-ID19388-87-5
RxCUI
ChEMBL IDCHEMBL2105420
ChEBI ID
PubChem CID
DrugBankDB12473
UNII ID8OBZ1M4V3V (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 677 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
15 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use